Birch Pollen Allergy: The PR-10 Allergen That Makes Raw Apple Itch Your Mouth

Birch pollen season in the US typically runs from late March through May, with peak pollen counts in April in most of the Northeast, Upper Midwest, Great Lakes, and Pacific Northwest. In the southern Appalachians and at mid-Atlantic elevations, the season begins slightly later, with peak occurring in April-early May. At higher Rocky Mountain elevations, birch seasons may extend into June. Exact timing shifts by 1-2 weeks depending on winter temperature — warmer springs produce earlier release. Climate change data show the overall season has lengthened by approximately 8 days since 1990 across North America. Monitoring a local National Allergy Bureau pollen station or pollen.com provides the most accurate daily count data for your specific region.

Raw apple OAS is the signature birch pollen cross-reactivity — caused by Mal d 1, the apple PR-10 protein that shares structural homology with Bet v 1. When your IgE antibodies recognize the Bet v 1 structure, they also bind to Mal d 1 in raw apple, triggering mast cell degranulation in the oropharyngeal mucosa — producing the characteristic itching, tingling, and mild lip or palate swelling within minutes of contact. Because PR-10 proteins are heat-labile, the cross-reactive epitope denatures with cooking — baked apple, cooked applesauce, and apple juice are typically tolerated well. This reaction is usually mild and self-limited, resolving within 20-30 minutes without treatment, but if you experience throat tightening, difficulty swallowing, or spreading hives after eating apple, seek evaluation for a more serious food allergy that may not be pure PR-10 OAS.

Not as an FDA-approved tablet. The Itulazax 12 SQ-Bet sublingual tablet is approved in more than 22 European countries and Canada for birch pollen allergic rhinitis, supported by high-quality RCT data. However, as of June 2026, Itulazax has not received FDA approval in the US. US birch SLIT uses off-label administration of non-standardized birch pollen extract as sublingual drops — a practice with supportive clinical evidence from European trials and a substantial track record of clinical use. Birch SCIT (allergy shots) using non-standardized extract has the longest evidence base in the US and is the more established option for patients willing to commit to weekly clinic visits during build-up. Both SLIT drops and SCIT are available through board-certified allergists in the US.

For the vast majority of patients with classic Bet v 1/Mal d 1 PR-10 OAS, no — cooked apple does not trigger reactions. PR-10 proteins denature at temperatures above approximately 60-65°C. Baked apple, cooked applesauce, and commercially canned apple are typically well tolerated by birch-OAS patients. Microwave heating for 90 seconds is sufficient to denature the relevant protein. Cold-pressed fresh apple juice is usually also tolerated because juicing and filtration removes most intact protein and the remaining PR-10 denatures quickly on contact with digestive enzymes. The key exception: if you have additional sensitization to apple via non-PR-10 proteins (such as Mal d 3, a heat-stable LTP), cooking would not eliminate that reaction. Component testing can distinguish PR-10-only from mixed sensitization.

Very likely yes. Anderegg et al. 2021 (PNAS e2013284118) analyzed 60 years of North American aerobiology data and found that total pollen loads increased by approximately 21 percent since 1990 and the pollen season lengthened by approximately 8 days. Tree pollen showed the largest proportional increase, driven primarily by higher temperatures in spring and earlier snow melt extending the growing season. Birch, as the dominant northern-latitude spring tree pollen allergen, participates in this trend. European phenology data confirm that birch pollen season is beginning progressively earlier — a change of 2-4 weeks since the 1980s in some regions. Patients who have managed their birch allergy stably for years may notice worsening symptoms without any change in their sensitization because the pollen dose they are exposed to each spring is genuinely higher.

Birch pollen allergy and hazelnut allergy can co-exist in two separate ways, which have very different clinical implications. The first is birch-driven OAS via Cor a 1 (hazelnut PR-10, a Bet v 1 homolog): this is heat-labile, causes mild oral symptoms only, and is part of the birch cross-reactivity package — often managed simply by roasting the hazelnut. The second is primary hazelnut food allergy via heat-stable storage proteins Cor a 9 (11S legumin) and Cor a 14 (2S albumin): this causes systemic reactions including anaphylaxis, is not related to birch pollen sensitization, and requires strict avoidance and epinephrine auto-injector prescription. Component testing distinguishing Cor a 1 from Cor a 9/14 IgE is essential for hazelnut allergy management — it determines whether you have the mild birch-related OAS or the more serious food allergy requiring epinephrine.

Most patients notice meaningful symptom improvement during the first treated spring season, which occurs after approximately 6-12 months of SCIT or SLIT. Full disease modification — the sustained reduction in allergen reactivity that persists after treatment ends — requires completing the full 3-5 year course. SCIT build-up involves weekly clinic injections for 4-6 months, then monthly maintenance. SLIT drops are started at any time and dosed daily at home throughout the full course. European SCIT trials for birch (Bodtger 2002; Arvidsson 2002) documented that benefits in seasonal rhinitis symptom scores and antihistamine medication use were statistically significant in the treated group by the second season and persisted for 3-7 years after treatment completion in follow-up studies.

Yes. Allergen immunotherapy for birch pollen is established in children and adolescents, and there is specific evidence suggesting that early treatment in children may reduce the risk of developing new sensitizations and may slow the atopic march from rhinitis to asthma. SCIT is generally used in children above age 5 years; SLIT drops are used in younger children in some clinical practices. European guidelines support early immunotherapy for tree pollen allergy in children with moderate-to-severe rhinitis and a positive skin prick test. Discuss timing, form (SCIT vs SLIT), and monitoring with a board-certified pediatric allergist. Starting immunotherapy before new sensitizations develop provides the most durable long-term benefit.

Bet v 1 is the major birch pollen allergen protein — a 17.5 kDa member of the PR-10 protein family, recognized by more than 90 percent of birch-allergic patients (Moverare 2002). When your allergy test reports a positive Bet v 1 IgE, it confirms that your immune system has produced specific IgE antibodies against this particular birch protein. Clinically, Bet v 1 positivity means you have the classic birch sensitization that drives spring rhinitis and PR-10 oral allergy syndrome to raw apple, cherry, hazelnut, and other foods with Bet v 1 homologs. Bet v 1-driven OAS is heat-labile (cooking the food is safe for most patients). The practical takeaway from a positive Bet v 1 result is that your spring rhinitis and your raw-apple mouth-itch share the same immune root — and targeting Bet v 1 with immunotherapy addresses both.

No — birch and oak are different species that release pollen at different times and are counted separately by aerobiology monitoring stations. Birch pollen peaks in April in most of the US Northeast and Midwest; oak pollen typically peaks slightly later in April-May and is a more dominant allergen in the southeastern US and mid-Atlantic regions. Both are Fagales-order trees with cross-reactive PR-10 allergens (Que a 1 shares 72-95% sequence identity with Bet v 1), meaning patients sensitized to birch frequently also have symptoms from oak. The National Allergy Bureau (AAAAI) and pollen.com provide species-level counts at many stations, allowing patients to distinguish birch-peak days from oak-peak days. This distinction matters for timing immunotherapy, tracking disease progression, and understanding why spring symptoms persist even after traditional birch season ends.